

CrossMark  
click for updates

# Correlation of pathologic findings of IgA nephropathy with clinical and laboratory data with regards to the Oxford-MEST-C classification

Mahoor Abedzadeh<sup>1</sup>, Azadeh Khayyat<sup>2</sup>, Mohammad Ali Esmail Pour<sup>3</sup>, Hamid Nasri<sup>1</sup>

<sup>1</sup>Nickan Research Institute, Isfahan, Iran

<sup>2</sup>Pathology Department of Medical College of Wisconsin, Milwaukee, WI, USA

<sup>3</sup>Internal Medicine Department of UNC Health Blue Ridge, Morganton, NC, USA

## Correspondence to:

Prof. Hamid Nasri, Email:  
hamidnasri@med.mui.ac.ir,  
hamidnasri@yahoo.com

Received: 9 May 2023

Accepted: 13 July 2023

ePublished: 26 July 2023

## Abstract

The Oxford classification system has been found to have significant correlations with clinical and laboratory data in patients with IgA nephropathy. Studies have shown that higher grades of mesangial hypercellularity and endocapillary hypercellularity are associated with younger age, higher blood pressure, and higher levels of proteinuria. Segmental glomerulosclerosis has been found to be associated with more severe proteinuria, lower serum albumin levels, and higher levels of creatinine. Tubular atrophy/interstitial fibrosis has been associated with older age, higher serum creatinine levels, and lower estimated glomerular filtration rates.

**Keywords:** IgA nephropathy, Oxford-MEST-C classification, Glomerulonephritis

**Citation:** Abedzadeh M, Khayyat A, Esmail Pour MA, Nasri H. Correlation of pathologic findings of IgA nephropathy with clinical and laboratory data with regards to the Oxford-MEST-C classification. J Prev Epidemiol. 2023;8(2):e35222. doi: 10.34172/jpe.2023.35222.

## Introduction

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is characterized by the deposition of IgA immune complexes in the glomeruli, leading to glomerular injury, proteinuria, and hematuria (1). Oxford classification, MEST, provides a scoring system to grade and stratify the severity of IgAN based on morphologic findings. This review will discuss the correlation of the pathologic conclusions of IgAN, oxford classification MEST with clinical and laboratory data (2,3).

## Search strategy

For this review, we searched PubMed/Medline, Directory of Open Access Journals, Web of Science, Google Scholar, EBSCO, Scopus, and Embase, using different keywords, including IgA nephropathy, Oxford classification, MEST-C score, glomerulonephritis, Oxford-MEST-C classification, end-stage renal disease and crescents.

## Oxford-MEST-C classification for IgA nephropathy

Mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy/

## Key point

The Oxford classification system is a valuable tool in evaluating, prognosis and managing IgA nephropathy patients.

interstitial fibrosis (T), and crescents (C), are the five elements evaluated in the Oxford classification, MEST-C scoring system. M and E are markers of active glomerular inflammation, whereas S and T reflect chronic and progressive glomerular injury, respectively (4,5). Numerous studies have shown a significant correlation between the Oxford classification MEST-C and clinical and laboratory data of IgAN patients, including the development of progressive renal dysfunction, proteinuria, and hematuria. In particular, S and T lesions on kidney biopsy are associated with a higher risk of progression to end-stage renal disease (ESRD) and a worse clinical outcome. Recent studies have also shown that the degree of tubular atrophy and interstitial fibrosis can provide important prognostic information independent of other pathological lesions (6,7). Furthermore, other factors like hypertension, advanced age, high baseline serum creatinine, and massive proteinuria, in conjunction with MEST lesions on kidney



biopsy, can further predict the risk of renal function decline in IgAN patients (8,9).

#### Possible limitations of the oxford-MEST classification

This classification system is based solely on morphologic findings and does not incorporate other clinical or laboratory data. The correlation of pathological conclusions like MEST-C lesions on kidney biopsy with clinical and laboratory data provides insight into disease progression, an indication of the type of treatment required, and a predictive guide of the disease's clinical course (10,11). There is a need for further studies that integrate clinical and laboratory data with the Oxford classification MEST-C scoring system to understand the pathogenesis better and develop appropriate management for IgAN patients (12,13). Some recent studies showed that interstitial inflammation, which is not incorporated in the MEST-C, is also associated with disease activity and development and is a neglected factor for prognosis like the other variables (14). The lack of inclusion of clinical data in the Oxford classification MEST scoring system may impact the accuracy of predicting long-term outcomes in IgAN patients. Clinical data, including patient age, comorbidities, and baseline renal function, can influence the progression and overall prognosis of IgAN. Without considering these factors, the MEST-C score may not accurately predict the risk of disease progression and clinical outcomes in individual patients (15,16). Previous studies showed that patients with lower baseline glomerular filtration rates and heavier proteinuria have been associated with worse clinical outcomes and a higher risk of progressing to ESRD. However, the Oxford classification MEST-C scoring system does not account for these patient-specific risk factors, which can limit its accuracy in predicting long-term outcomes (17).

Moreover, a few studies have suggested that incorporating clinical and laboratory data can improve the MEST-C score's accuracy in predicting long-term outcomes in IgAN patients. For instance, adding serum levels of creatinine, proteinuria, and blood pressure measurements to the MEST score can enhance its accuracy in predicting renal outcomes and the progression of IgAN. This suggests the need for a more comprehensive approach to scoring, such as adding clinical data to the Oxford classification MEST-C system to enhance its ability to predict outcomes (18,19) accurately.

Previous investigations have demonstrated the numerous benefits of utilizing the clinical data for the Oxford classification MEST-C scoring system in IgAN patients as follows:

#### Enhanced accuracy in predicting long-term outcomes

This enables better risk stratification and helps differentiate high-risk patients for whom therapeutic interventions or follow-up regimes should be stepped up (20).

#### Individualized patient care

Incorporation of clinical data with the MEST score can provide a more personalized approach to disease management. Individualized treatment guidelines can be developed by providing clinicians with a more comprehensive evaluation of the patient's condition, accounting for the particular patient's clinical profile (21).

#### Reproducibility and consistency

Incorporating clinical data reduces inter-observer variability between pathologists reviewing biopsy specimens, improving the consistency and reproducibility of the MEST-C score (22).

#### A better understanding of disease progression

Combining clinical and morphological data can help provide a better insight into the pathogenesis of IgAN. This can lead to discovering previously unreported pathways contributing to disease development or help identify patients with uniquely severe or rapidly progressing renal disease, who may have been previously missed based solely on morphological features (23, 24).

#### Conclusion

Incorporation of clinical data with the MEST-C score can help patients better understand the diagnosis, prognosis, and expected clinical outcomes, allowing informed decision-making and leading to better collaboration and patient engagement in their medical care.

#### Authors' contribution

**Conceptualization:** Hamid Nasri.

**Data curation:** Hamid Nasri and Mahoor Abedzadeh.

**Funding acquisition:** Mahoor Abedzadeh.

**Investigation:** Mahoor Abedzadeh.

**Resources:** Hamid Nasri.

**Supervision:** Hamid Nasri.

**Validation:** Hamid Nasri and Mahoor Abedzadeh.

**Visualization:** Hamid Nasri, Azadeh Khayyat.

**Writing—original draft:** Mahoor Abedzadeh, Hamid Nasri.

**Writing—review and editing:** Mahoor Abedzadeh, Azadeh Khayyat, Mohammad Ali Esmaeil Pour.

#### Conflicts of interest

The authors declare that they have no competing interests.

#### Ethical issues

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

#### Funding/Support

None.

#### References

1. Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. *Am J Med Sci.* 2021;361:176-194. doi: 10.1016/j.amjms.2020.10.003.
2. Nasri H, Mortazavi M, Ghorbani A, Shahbazian H, Kheiri S, Baradaran A, et al. Oxford-MEST classification in IgA nephropathy patients: A report from Iran. *J Nephrothol.*

- 2012;1:31-42. doi: 10.5812/jnp.7.
3. Itami S, Moriyama T, Miyabe Y, Karasawa K, Nitta K. A novel scoring system based on Oxford classification indicating steroid therapy use for IgA nephropathy. *Kidney Int Rep.* 2021 Oct 14;7:99-107. doi: 10.1016/j.ekir.2021.10.007.
  4. Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. *Kidney Intern.* 2017;91:1014-21.
  5. Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. *Clin J Am Soc Nephrol.* 2019 Mar 7;14:469-481. doi: 10.2215/CJN.08600718.
  6. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. *Kidney Int.* 2011;80:310-7. doi: 10.1038/ki.2011.126.
  7. Park KS, Han SH, Kie JH, Nam KH, Lee MJ, Lim BJ, et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy. *Hum Pathol.* 2014;45:236-43. doi: 10.1016/j.humpath.2013.08.019.
  8. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. *Am J Kidney Dis.* 2012;59:865-73. doi: 10.1053/j.ajkd.2012.02.326.
  9. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. *Kidney Int.* 2004;66:1606-12. doi: 10.1111/j.1523-1755.2004.00926.x.
  10. Roberts IS. Pathology of IgA nephropathy. *Nat Rev Nephrol.* 2014;10:445-54. doi: 10.1038/nrneph.2014.92.
  11. Selvaskandan H, Shi S, Twaij S, Cheung CK, Barratt J. Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management. *Front Immunol.* 2020 Oct 6;11:572754. doi: 10.3389/fimmu.2020.572754.
  12. Xie J, Lv J, Wang W, Li G, Liu Z, Chen H, et al. Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients. *Am J Kidney Dis.* 2018;72:371-380. doi: 10.1053/j.ajkd.2018.01.043.
  13. Soares MFS, Roberts IS. Histologic Classification of IgA Nephropathy: Past, Present, and Future. *Semin Nephrol.* 2018;38:477-484. doi: 10.1016/j.semnephrol.2018.05.017.
  14. Asrar I, Hussain M, Afzal A, Hassan U, Ishtiaq S. Blind Spot in the Radar of MEST-C Score: Type and Severity of Tubulointerstitial Nephritis in IgA Nephropathy. *Int J Nephrol.* 2023;2023:1060526. doi: 10.1155/2023/1060526.
  15. Dhaun N, Bellamy CO, Cattran DC, Kluth DC. Utility of renal biopsy in the clinical management of renal disease. *Kidney Int.* 2014;85:1039-48. doi: 10.1038/ki.2013.512.
  16. Seikrit C, Rauen T, Stamellou E, Floege J. Precision medicine in immunoglobulin A nephropathy: still a journey ahead. *Nephrol Dial Transplant.* 2021;36:24-30. doi: 10.1093/ndt/gfab032.
  17. Tonelli M, Klarenbach SW, Lloyd AM, James MT, Bello AK, Manns BJ, et al. Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria. *Kidney Int.* 2011;80:1306-14. doi: 10.1038/ki.2011.280.
  18. Liu Y, Zhang Y, Liu D, Tan X, Tang X, Zhang F, et al. Prediction of ESRD in IgA Nephropathy Patients from an Asian Cohort: A Random Forest Model. *Kidney Blood Press Res.* 2018;43:1852-1864. doi: 10.1159/000495818.
  19. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. *PLoS One.* 2012;7:e38904. doi: 10.1371/journal.pone.0038904.
  20. Zhang Y, Guo L, Wang Z, Wang J, Er L, Barbour SJ, et al. External Validation of International Risk-Prediction Models of IgA Nephropathy in an Asian-Caucasian Cohort. *Kidney Int Rep.* 2020;5:1753-1763. doi: 10.1016/j.ekir.2020.07.036.
  21. Boyd CM, Darer J, Boulton C, Fried LP, Boulton L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA.* 2005;294:716-24. doi: 10.1001/jama.294.6.716.
  22. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. *Kidney Int.* 2009;76:546-56. doi: 10.1038/ki.2009.168.
  23. Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. *Pediatr Nephrol.* 2018;33:763-777. doi: 10.1007/s00467-017-3699-z.
  24. Haaskjold YL, Bjørneklett R, Bostad L, Bostad LS, Lura NG, Knoop T. Utilizing the MEST score for prognostic staging in IgA nephropathy. *BMC Nephrol.* 2022;23:26. doi: 10.1186/s12882-021-02653-y.